Dare Bioscience, Inc.
About Dare Bioscience, Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.0M
- Net income
- -$13.4M
- Total assets
- $32.5M
- Market cap
- $28.2M
- Gross margin
- 71.3%
- Operating margin
- -1315.5%
- Net margin
- -1300.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.0M
- Cost of revenue
- $295.8K
- Gross profit
- $734.4K
- Operating expenses
- $14.3M
- Operating income
- -$13.6M
- Income tax
- $0
- Net income
- -$13.4M
- EPS (basic)
- $-1.20
- EPS (diluted)
- $-1.20
Balance sheet
- Total assets
- $32.5M
- Current assets
- $27.1M
- Total liabilities
- $29.6M
- Current liabilities
- $23.7M
- Shareholders’ equity
- $2.8M
Cash flow
- Operating cash flow
- -$9.9M
- Investing cash flow
- -$385.3K
- Financing cash flow
- $19.3M
- Net cash flow
- $9.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $28.2M
- EPS (diluted)
- $-1.2
- Shares outstanding
- 15.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 10, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $13.4M in FY2025.
- Gross margin of 71.3%, net margin -1300.7%.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Dare Bioscience, Inc..
Write a review
News about Dare Bioscience, Inc.
News & sentiment via Polygon.io
